Core Viewpoint - The article discusses the significant impact of centralized procurement policies on the traditional Chinese medicine (TCM) industry, highlighting the challenges and potential restructuring within the sector as it enters a new era of competition and pricing pressures [1][2][3]. Group 1: Impact of Centralized Procurement - The centralized procurement system has greatly affected the Western medicine industry, and similar pressures are now being felt in the TCM sector as it officially enters the "procurement era" [1][3]. - The scope of centralized procurement for TCM has expanded from 15 provinces to nationwide, with the number of products increasing to 45, indicating a growing impact on the industry [10][9]. - Many selected companies are pricing their products close to cost, leading to expectations of profit declines in the TCM industry by 2025 [11][12]. Group 2: Market Dynamics and Price Trends - Despite the challenges, the price of raw materials for TCM has significantly decreased this year, with the Chinese herbal medicine price index dropping over 20% from its peak [14][13]. - Some companies that won bids in the procurement process are experiencing unexpectedly high profits due to fixed hospital procurement prices, leading to optimistic sales forecasts [17]. - The average price drop for selected products in the latest procurement round was 47.38%, with some products seeing reductions as high as 69.3% [37][38]. Group 3: Industry Restructuring and Future Outlook - The TCM industry is expected to undergo significant restructuring, with a potential reduction in the number of suppliers as centralized procurement becomes more prevalent [23][24]. - The government has issued policies aimed at enhancing the quality and development of the TCM industry, indicating a push towards modernization and improved standards [25]. - The performance of TCM companies has been under pressure, with a reported 4.6% decline in total revenue and an 18.7% drop in net profit for 75 listed TCM companies in 2024 [29][28]. Group 4: Competitive Landscape - The competitive landscape is shifting, with traditional TCM giants facing challenges as their unique product strategies are tested by centralized procurement [33][40]. - Companies that previously opted out of insurance reimbursement to avoid price cuts are now facing increased pressure as more exclusive products enter centralized procurement [34][36]. - The article suggests that only companies with strong R&D capabilities, unique products, and brand advantages will thrive in the increasingly competitive environment [44][42].

作者 | 远禾 数据支持 | 勾股大数 据（www.gogudata.com） 近几年来，集采制度极大冲击了西药行业。 去年年底，全国范围的中药饮片、中成药集采同时启动，折射出中药行业也并不太平。 今年 5月，全国约10个省份开始落实第一次全国中药饮片集采的中标结果，中药饮片正式迈入"集采时代"。 4月以来，中证中药指数却从最低的9051点一路上涨至6月3日的10054点，两个月内上涨超10%。 最近，中证中药指数又开始接连大幅下跌。 在没有安全区的集采政策里，中药企业正在面临更为严重的冲击。 而在去年的中药饮片联采中，集采范围从最开始的 15个省市扩大到了全国，品种数量也翻倍，增加到了45个品种，对行业的影响逐步扩大。 彼时，许多中选企业的报价已经近乎成本价，甚至部分企业仍处于战略性亏损状态。 也是因此，集采中选后，不少企业预计 2025年公司利润会整体下滑，中药行业也将遭受一定打击。 然而，今年以来，中药材原料价格显著回落。 康美中国数据显示，中药材价格指数在 2024年7月达到阶段高点2245点左右，随后一路下跌，如今已跌至1772左右，同比下跌超20%。 十二大类中仅 1类上涨，其余11类下跌，尤以植 ...